1)Crona J, et al:New perspectives on pheochromocytoma and paraganglioma;Toward a molecular classification. Endocr Rev 38:489-515, 2017
2)Lenders JW, et al:Pheochromocytoma and paraganglioma;An endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915-1942, 2014
3)日本内分泌学会(監),日本内分泌学会「悪性褐色細胞腫の実態調査と診療指針の作成」委員会(編):褐色細胞腫・パラガングリオーマ診療ガイドライン2018.日内分泌会誌94(Suppl):i-87,2018
4)方波見卓行:クロニジン試験.成瀬光栄,他(編):内分泌機能検査実施マニュアル(改訂第3版),p87,診断と治療社,2019
5)Lenders JW, et al:Pheochromocytoma. Lancet 366:665-675, 2005
6)Plouin PF, et al:European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174:G1-G10, 2016
7)Kimura N, et al:Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21:405-414, 2014
8)Yamazaki Y, et al:Recent advances in histopathological and molecular diagnosis in pheochromocytoma and paraganglioma;Challenges for predicting metastasis in individual patients. Front Endocrinol(Lausanne)11:587769, 2020
9)Casey R, et al:Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma;Implications for precision medicine. Hum Mol Genet 29:R128-R137, 2020